FDA to Ask Sarepta to Halt Elevidys Shipments
Digest more
The Food and Drug Administration has updated their recall of a batch of Dubai chocolate spread to Class I, their highest level, due to risk of salmonella contamination.
The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's antipsychotic drug in combination with Viatris' antidepressant Zoloft for treating adults with PTSD.
The FDA authorized Juul’s applications on Thursday to sell e-cigarettes in the U.S., determining they’re “appropriate for the protection of public health” because their benefits to adult smokers of combustible cigarettes outweigh the risks to nonsmoking youths.
Health officials have recalled two products produced by Chenak LLC, which has a location in Sugarland, for ties to a salmonella outbreak.
A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on hormone treatments for menopause, arguing that the strong warning has likely discouraged countless women from using a treatment that may provide benefit.
Explore more
Rich Ice Cream Co. recalled numerous lots of its products on June 27 over potential contamination with Listeria monocytogenes.
FRIDAY, July 18, 2025 (HealthDay News) — After years of legal battles and health concerns, Juul Labs has the go-ahead to sell some of its electronic cigarettes in the United States. The U.S. Food and Drug Administration (FDA) said that it will allow Juul to market its e-cigarette device and tobacco and menthol refill cartridges.
The manufacturer announced a recall of 67,214 cases of its Power Stick roll-on deodorant due to violations of Current Good Manufacturing Practices.
The regulator authorized the company to keep its e-cigarettes on the U.S. market after a federal ban in 2022 had pushed it to the brink of bankruptcy.
The Food and Drug Administration is reassessing some warnings given about hormone therapy treatments for menopause that have led to some women avoiding the option, even if it could help them.
The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's drug when used in combination with Viatris' Zoloft for the treatment of adults with PTSD.
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.